Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00135304
Status:
COMPLETED
Last Update Posted:
2014-02-11
First Post:
2005-08-24
Brief Title:
ACHIEVE Optimizing the Treatment of Secondary Hyperparathyroidism
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
ACHIEVE Optimizing the Treatment of Secondary Hyperparathyroidism A Comparison of Sensipar and Low Dose Vitamin D vs Escalating Doses of Vitamin D Alone
Status:
COMPLETED
Status Verified Date:
2014-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the proportion of chronic kidney disease CKD subjects on dialysis receiving Sensipar and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative NKF-KDOQI secondary hyperparathyroidism HPT treatment targets for both biointact parathyroid hormone biPTH and calcium-phosphorus Ca x P product
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None